Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study

Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study

ABSTRACT Introduction The clinical application of lazertinib, a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has extended to the treatment of EGFR‐mutant non‐small‐cell lung cancer (NSCLC); however, the effects of its dose modification on its efficacy and safet...

Full description

Saved in:
Bibliographic Details
Main Authors: Mi‐Hyun Kim, Min Ki Lee, Ji Eun Park, Sun Hyo Park, Tae Won Jang, Chi Young Jung, Insu Kim, Seong Hoon Yoon, June Hong Ahn, Hyun‐Kyung Lee, Jin Han Park, Sun Ha Choi, Jung Seop Eom
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Thoracic Cancer
Subjects:
dose modification
epidermal growth factor receptor
lazertinib
treatment outcome
Online Access:https://doi.org/10.1111/1759-7714.70083
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/1759-7714.70083

Similar Items